INOVIO Reports Inducement Grants Under Inducement Plan
Date
10/2/2024 4:31:03 PM
(MENAFN- PR Newswire)
PLYMOUTH MEETING, Pa., Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO ),
a biotechnology company focused on developing and commercializing DNA medicines to
help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made
equity grants to
certain
employees
under its 2022 Inducement Plan (the "Inducement Plan").
The Compensation Committee of INOVIO's Board of Directors has approved
the
awards of restricted stock units ("RSU"s) covering an aggregate of 1,526
shares of common stock and options to purchase an aggregate of 1,600
shares of common stock, each with a grant date of September
30, 2024
(the "Grant Date"), to two newly
hired employees in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The stock options have an exercise price of $5.78, the closing price of INOVIO's common stock on the Grant Date. The stock options will vest and become exercisable with respect to one-fourth of the shares underlying the stock options on the Grant Date, and an additional one-fourth of the shares underlying the stock options on the first, second, and third anniversaries of the Grant Date. The vesting of the RSUs and stock options will be subject to the employees' continued employment with INOVIO on the applicable vesting dates. Each of these awards is subject to the terms and conditions of a stock option agreement or RSU
award agreement, as applicable, under the Inducement Plan.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit .
Contacts
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Thomas Hong, (267) 440-4298, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN02102024003732001241ID1108741030
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.